3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
14
Specimen Handling
8
Docetaxel
8
olaparib
7
Nivolumab
7
Gemcitabine
7
Trastuzumab
6
Paclitaxel
6
rucaparib
5
Magnetic Resonance Spectroscopy
5
Early Intervention, Educational
5
Biopsy
5
Standard of Care
4
Cyclophosphamide
4
Carboplatin
4
tisotumab vedotin
3
talazoparib
3
pertuzumab
3
durvalumab
3
atezolizumab
3
Taxes
3
Surveys and Questionnaires
3
Sirolimus
3
Radiotherapy
3
Psychiatric Rehabilitation
3
Methods
3
Irinotecan
3
Immunoglobulin G
3
Fulvestrant
3
Educational Status
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Interleukin-15
×
Gynecologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled